B. Riley reiterates a Buy rating on Gritstone bio with a $3 price target following the Q1 report. Recent equity weakness is attributed to “disappointing” circulating tumor DNA primary efficacy results that overshadowed better than expected preliminary progression free survival dataset, which has further room for improvement, the analyst tells investors in a research note. The firm says the GRANITE-CRC-1L colorectal cancer study miss on the primary endpoint was the result of trial design failure, not product failure.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRTS:
- Gritstone price target lowered to $4 from $7 at H.C. Wainwright
- Gritstone reports Q1 EPS (34c), consensus (32c)
- Gritstone highlights durability, potential utility of samRNA COVID-19 vaccine
- Gritstone Oncology Announces Board of Directors Changes
- Gritstone appoints Stephen Webster to board of directors